New drug duo aims to boost immune attack on tough cancers
NCT ID NCT05789069
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HFB200603 (an experimental antibody) and tislelizumab (an approved immunotherapy)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced cancers like kidney, lung, or melanoma that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 83 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, 80131, Italy
-
New Experimental Therapeutics of Virginia - NEXT Oncology
Fairfax, Virginia, 22031, United States
-
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, 28050, Spain
-
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, 00168, Italy
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States